Description
LG190119 is a nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. LG190119 effectively inhibited LNCaP xenograft tumor growth without increased serum calcium levels or any other apparent side effects. Compounds of this class may represent promising new therapeutics for treatment of prostate cancer and other cancers with fewer undesirable side effects than currently used drugs.
Uses
J1075 is a selective Schistosoma mansoni HDAC8 modulator (with decreased affinity for human HDAC8). J1075 can induce apoptosis (Apoptosis) and death in schistosome cells. J1075 holds research value in the field of anti-parasitic agents[1].
in vivo
In the established tumor study, LG190119 at each dose resulted in significant tumor growth inhibition without hypercalcemia at both 10 and 15 days. LG190119 effectively inhibited LNCaP xenograft tumor growth without increased serum calcium levels or any other apparent side effects._x000D_
_x000D_
Reference: Prostate. 2001 Nov 1;49(3):224-33. https://pubmed.ncbi.nlm.nih.gov/11746268/
target
LG190119 is a nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium.
References
[1] Polek TC, et al. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate. 2001 Nov 1;49(3):224-33. DOI:
10.1002/pros.1138
